Tirzepatide 15mg (30 Day Protocol)

Description

Tirzepatide is the first dual-action incretin mimic, targeting both GIP and GLP-1 receptors, which has shown superior weight loss results compared to GLP-1 mono-agonists. Our 15mg (30-Day Protocol) is designed for patients who have completed initial titration and require the maximum maintenance dose to achieve sustained weight management goals.

• Maximum Therapeutic Dose: 15mg once weekly is the maximum dosage, which clinical trials (SURMOUNT-1) showed can lead to significant body weight reduction, with some participants losing over 20% of their body weight.
• Dual-Action Hormone Therapy: Simultaneously activates GIP and GLP-1 receptors to optimize metabolic function, increase insulin sensitivity, and enhance satiety.
• Appetite Control & Reduced Cravings: Actively suppresses hunger signals and slows gastric emptying, helping you feel satisfied with smaller portions and curbing cravings.
• Convenient Weekly Dosing: Simple, once-weekly subcutaneous injection designed for at-home administration.
• Metabolic & Cardiovascular Health: Supports healthy blood sugar regulation and lipid profiles.